Published finding — does the expert body still believe it?
Durvalumab consolidation therapy after platinum-based chemoradiotherapy significantly improves median progression-free survival (16.8 months vs. 5.6 months; HR 0.52) compared to placebo in patients with unresectable stage III NSCLC who did not progress after chemoradiotherapy.
TL;DR · AI-generated
Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Author-implied confidence
95%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
98% → 98% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
· openalex W2753065806 · s2 bc101251
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0477
Durvalumab consolidation after chemoradiotherapy in stage III NSCLC significantly prolongs the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months; P<0.001).
0.0644
Durvalumab consolidation therapy produces a significantly higher objective response rate than placebo (28.4% vs. 16.0%; P<0.001) in stage III NSCLC patients following chemoradiotherapy.
0.0877
Durvalumab consolidation after chemoradiotherapy will demonstrate a statistically significant overall survival benefit in the final analysis of the PACIFIC trial in stage III unresectable NSCLC.
0.1449
Grade 3 or 4 adverse events, including pneumonia, occur at similar rates in durvalumab-treated (29.9%) and placebo-treated (26.1%) stage III NSCLC patients receiving consolidation therapy after chemoradiotherapy.
0.1933
In previously untreated patients with unresectable stage III/IV melanoma, nivolumab plus ipilimumab achieves a median progression-free survival of 11.5 months versus 2.9 months with ipilimumab alone (HR 0.42, P<0.001).
0.2047
The KEYNOTE-189 trial's stated primary conclusion — Pembrolizumab plus chemotherapy improves overall survival in metastatic non-squamous NSCLC without targetable mutations. — replicates in independent cohorts.